News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2021

March

Media Release / Mar 23, 2021

Health Canada approves Kesimpta®, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis (RRMS)

Read More
Media Release / Mar 18, 2021

Novartis’ KISQALI® (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer

Read More
2020

December

Media Release / Dec 16, 2020

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Read More

November

Media Release / Nov 02, 2020

Novartis’ MONALEESA-7 KISQALI® (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer

Read More

October

Media Release / Oct 21, 2020

Novartis in Canada driving digital healthcare solutions with the inauguration of a Biome innovation hub

Read More
Media Release / Oct 16, 2020

Health Canada approves first-ever gene replacement therapy, Luxturna®

Read More
Media Release / Oct 02, 2020

Next-generation wet AMD therapy PrBeovu® now available in Canada receives positive recommendation from CADTH Drug Expert Committee1

Read More

August

Media Release / Aug 18, 2020

16th annual Novartis Ride for Life™ goes virtual to raise funds for cancer research

Read More
Media Release / Aug 12, 2020

PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer

Read More

July

Media Release / Jul 16, 2020

Novartis in Canada certified as a Great Place to Work® for a second consecutive year

Read More